Is Now The Perfect Time To Buy AstraZeneca plc, Greggs plc And Stanley Gibbons Group PLC?

Are these 3 stocks ripe for investment? AstraZeneca plc (LON: AZN), Greggs plc (LON: GRG) and Stanley Gibbons Group PLC (LON: SGI)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Turning companies around from disappointing financial performance to superb profitability is never an easy task. After all, there is usually a very good reason for their bottom lines falling, whether that is a change in customer tastes, a recession or poor decisions by management which have caused the business to become uncompetitive. And, even if the right strategy is put in place, it usually takes a considerable amount of time for even the best of companies to mount a successful comeback.

One stock which is very much on the up is AstraZeneca (LSE: AZN). It has endured a very challenging period of time with a number of key, blockbuster drugs coming off patent and being exposed to generic competition. However, it was a poor response by the business which led to its downfall, since it lacked a strong pipeline of new drugs to take the places of the ones which lost patent protection. Furthermore, policies such as a major share buyback were using up vital cash resources which could have been better spent on improving the company’s long term outlook.

However, under a different management team, AstraZeneca has got its house in order. It has embarked on a highly successful acquisition spree, with its sound balance sheet and excellent cash flow being used to bring on board a number of new drugs and potential treatments which, in years to come, could become blockbuster drugs for the business. And, while the company’s share price has soared by 46% since the start of 2013 (while also paying a yield of 6.1% throughout the period), its shares trade on a relatively appealing price to earnings (P/E) ratio of 15.4.

Also making a successful turnaround is high-street food business Greggs (LSE: GRG). It lost its way under previous management, with the business attempting to diversify its offering through more upmarket coffee shops and a range of chilled/frozen foods on sale in supermarkets. In other words, it appeared to lose focus on its core offering but, under a different management team, Greggs has become a more efficient and simple business. For example, it has closed unprofitable stores, improved its supply chain and focused on giving customers what they want: good value food in convenient locations.

Furthermore, today’s update from Greggs is very positive. It has reported strong sales in a low inflation environment and expects its full-year results to be ahead of market expectations. As such, its shares are up by 6% today, making it a gain of 56% since the turn of the year.

However, Greggs is likely to see margins squeezed in future years from the impact of the new living wage. And, while it already pays its staff a higher rate than the minimum wage, for a business which is focused on value it may be unable to pass all of the additional costs on to consumers.

Meanwhile, collectibles company Stanley Gibbons (LSE: SGI) appears to be in need of a turnaround, with its shares slumping by 27% today after a profit warning. It continues to struggle with a slowing Asian economy and, while it states in today’s update that its second half performance will be much better than its first, margins are coming under increasing pressure.

As a result, its short term performance is likely to be rather disappointing and its shares may continue the run which has seen them fall by 62% since the turn of the year. However, Stanley Gibbons remains a financially sound, niche business which has long term potential to recover as the world economy stabilises. And, with it having a price to book value (P/B) ratio of just 0.8, it appears to be worth buying for the long term.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

Forecasts are down, but I see a bright future for FTSE 100 dividend stocks

Cash forecasts for UK dividend stocks are falling... time to panic! Actually, no. I reckon the future has never looked…

Read more »

Young female analyst working at her desk in the office
Investing Articles

Down 13% in April, AIM stock YouGov now looks like a top-notch bargain

YouGov is an AIM stock that has fallen into potential bargain territory. Its vast quantity of data sets it up…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

Beating the S&P 500? I’d buy this FTSE 250 stock for my Stocks and Shares ISA

Beating the S&P 500's tricky, but Paul Summers is optimistic on this FTSE 250 stock's ability to deliver based on…

Read more »

Passive and Active: text from letters of the wooden alphabet on a green chalk board
Investing Articles

2 spectacular passive income stocks I’d feel confident going all in on

While it's true that diversification is key when it comes to safe and reliable investing, these two passive income stocks…

Read more »

Investing Articles

The easyJet share price is taking off. I think it could soar!

The easyJet share price is having a very good day. Paul Summers takes a look at the latest trading update…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

9 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

As the Rentokil share price dips on Q1 news, I ask if it’s time to buy

The Rentokil Initial share price has disappointed investors in the past 12 months. Could this be the year we get…

Read more »

Growth Shares

Could dirt cheap Volex be one of the best UK stocks to buy today?

When looking for stocks to buy, it can pay to seek out long-term growth potential at a reasonable price. One…

Read more »